Biotech Values

[GrthzGd]

SNY down 5.5% more after hours. From the MarketWatch comment:

Viehbacher’s appointment in December 2008 was presented as a major cultural shift to internationalize Sanofi beyond its traditional French and European strongholds. But while the CEO’s efforts to steer the company into new areas of business has helped revive growth after Sanofi lost patents on some of its best-selling drugs, his open criticism of past research failures, and emphasis on the U.S. market has upset French labor unions and many French government officials.

Terminating a CEO for other than business reasons is never a good idea.